usdaed

The roll call of integrated energy giants is a sparse gallery: Chevron, Exxon, TotalEnergies, BP, Shell. Yet BP and Shell, with their half-hearted flirtations with clean energy, have left a stain on their dividend records, a blemish that lingers like an indelible ink on parchment. Their recent reversals of fortune-abandoning green pledges as readily as one discards a moth-eaten coat-render them less than ideal companions for the long-haul investor. Thus, the stage is set for the triumvirate of Chevron, Exxon, and TotalEnergies to bask in the limelight of dividend reliability.

Humira, once the jewel in AbbVie’s crown, has become the cautionary tale of biosimilars. Its sales have dwindled like a tide retreating from a sandy shore since 2023. Yet, where one door closes, two successors-Skyrizi and Rinvoq-swagger in with such confidence that even a cynic might raise an eyebrow. These two drugs are on track to outearn Humira at its peak, a feat that would make a goldfish blush.

After a 2024 outage that made their reputation about as stable as a TikTok trend, CrowdStrike’s net new ARR is set to hit 40%+ growth in the back half of 2026. Translation: Renewals and upsells are healing faster than a Netflix reboot. The newer modules (you know, the ones with acronyms longer than a SpaceX invoice) are pulling their weight, making deal sizes puff up like a Victoria’s Secret ad. For subscription models, this is the financial equivalent of finding money in last winter’s coat pocket – it’s early, it’s juicy, and it smells like Q4 bonuses.

The S&P 500, that venerable club of 500 corporations, operates under rules so specific it makes the selection process for the Wimbledon finals look positively casual. A company needs $22.7 billion in market cap, profitability, and a U.S. exchange listing-though final approval rests with a committee that meets quarterly, presumably in a mahogany-paneled room with velvet curtains and a ouija board.

Apple (AAPL)’s stumble into the artificial intelligence epoch was less of a triumph and more of a misstep, to put it politely. The company’s October 2024 unveiling of Apple Intelligence, while brimming with promise, failed to stir the masses-or their pocketbooks. The result? A rather unseemly dip in share price, from $256 to $188, as investors exchanged glances over lukewarm coffee. Yet, as the seasons turned, so too did fortune’s wheel. Consumers, it seems, were equally unprepared to wade into AI’s murky waters, preferring to let the kinks be ironed out by others. Now, both parties-Apple and its clientele-find themselves primed for a more harmonious duet.

But here’s the catch: GPUs aren’t cheap. They cost a fortune, and creating the infrastructure to house them? Well, that’s another story entirely. Imagine building a spaceship, and then filling it with engines that cost as much as your house. Sounds fun, right? But not exactly something you can do on a whim. Still, the world is screaming for more AI computing power, and big tech companies can’t sit around twiddling their thumbs while their data centers slowly take shape.

Let’s dive into two cryptocurrencies making waves: Shiba Inu (SHIB) and TRON (TRX). If you’re thinking of turning a measly investment into a million dollars, the optimism is palpable. But, can these coins genuinely live up to that lofty dream? Spoiler alert: it’s going to take a Herculean effort…and maybe a bit of luck, too.